News
-
-
PRESS RELEASE
Sartorius Stedim Biotech réalise une croissance rentable importante en 2025 et maintient des perspectives positives
Sartorius Stedim Biotech réalise une croissance rentable en 2025 et maintient des perspectives positives. Chiffre d'affaires en hausse de 9,6% à taux de change constants. EBITDA à 914 millions d'euros. Perspectives de croissance rentable pour 2026 -
-
PRESS RELEASE
Medacta Group SA: Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025
Medacta Group SA reports 18.5% revenue growth in 2025, with strong performance in all geographic markets and business lines. New jobs created to drive further expansion -
-
PRESS RELEASE
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach -
-
-
-